Gilead's Trodelvy Misses Primary Endpoint In Phase 3 ASCENT-07 Breast Cancer Study

(RTTNews) - Gilead Sciences, Inc. (GILD) on Friday reported that the Phase 3 ASCENT-07 study, evaluating Trodelvy versus chemotherapy as a first-line treatment after endocrine therapy in HR+/HER2-negative metastatic breast cancer, did not meet its primary endpoint of progression-free survival (PFS).

Trodelvy is currently being studied in multiple Phase 3 trials across various tumor types.

The drug is approved in more than 50 countries for second-line or later treatment of metastatic triple-negative breast cancer (TNBC) and in over 40 countries for certain patients with pre-treated HR+/HER2-negative metastatic breast cancer.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.